TGA flags illegal waitlists for unapproved oral weight-loss pills

There is a growing market for something that does not yet exist in Australia: an approved oral GLP-1 weight-loss medicine. According to the Medical Republic, the TGA has moved to address it — warning telehealth providers that promoting waitlists for unapproved oral GLP-1 products could breach Australian advertising law, with penalties reaching $18.2 million per offence. The TGA’s message is specific: marketing an unapproved medicine, including by collecting expressions of interest, crosses into regulated territory.

No oral semaglutide and no oral tirzepatide has received TGA approval in Australia. What has been approved — injectable semaglutide (Ozempic, Wegovy) and injectable tirzepatide (Mounjaro) — is already in shortage. That gap is the commercial opportunity some telehealth services are attempting to occupy before any regulatory pathway exists.

Why this is landing now

The demand side of this equation is not a mystery. GLP-1 medicines are producing real clinical results. Injectable GLP-1s have transformed the weight management conversation in general practice over the past two years, but access remains genuinely difficult: supply shortages, inconsistent PBS coverage, and the reality that many patients find the injection barrier — practical, psychological, or both — significant. An oral version would remove that barrier for many people.

That is the legitimate patient need that telehealth marketing is speaking to. The problem is not the demand. The problem is that “joining a waitlist” is not a clinical pathway — it is a data-collection mechanism, and in this context, it may constitute advertising of an unapproved therapeutic good.

Both and

Here is where it is worth sitting with both sides of this.

On one hand: GLP-1 medicines have meaningful evidence behind them, patients are genuinely struggling to access appropriate care, and some degree of consumer interest in what is coming is not irrational. Oral semaglutide does exist in other markets. It is not fanciful. And the TGA’s advertising provisions, while important, can feel blunt in an environment where patients are actively seeking information about their options.

On the other hand: an unapproved product carries no regulatory safety review, no confirmed dosing guidance for this indication, and no prescription pathway. Being added to a waitlist creates no clinical relationship, no screening, no assessment of appropriateness, and no informed consent. A patient who has seen the marketing and done the research may have a view about the risk — but a patient who joined a waitlist because they trust a telehealth brand may not. That asymmetry is why the TGA’s intervention matters.

The $18.2 million figure is not symbolic. It signals that the TGA is prepared to treat this as serious commercial misconduct, not a grey-area technicality.

2 cents

Patients are going to bring this to the consult. Some will be enthusiastic. Some will be confused about what they have signed up for. The conversation is actually not complicated once you have the frame.

What to say: “There’s no approved oral GLP-1 in Australia yet — what you’ve joined is a marketing list, not a clinical waitlist. Let’s talk about what you can access now.” That single reframe does most of the work. It is not dismissive of the person’s goal; it redirects toward an actual pathway.

Check injection resistance specifically. For many patients who have been drawn to an oral option, the barrier to injectables is the real clinical problem. If it is practical (supply, cost, GP visits), there are workarounds worth discussing. If it is psychological, that is worth naming directly — many people who feel strongly about not injecting shift once the clinical context is clear and the process is demystified.

For GPs using telehealth platforms: this is also a prompt to review what platforms you or your practice are affiliated with, and whether any are operating adjacent to this kind of pre-marketing. The TGA’s warning is about providers, not patients — but the reputational and regulatory exposure is real.

The access problem in GLP-1 prescribing is real. The waitlist marketing is not a solution to it. Patients deserve a clearer picture of where the actual pathway sits.

Verdict: yes — GPs need to know this is happening before patients ask, and the reframe is simple.

---

Sources cited

1. TGA warns on weight-loss pill waitlists — Medical Republic